Biotech Patents and Section 101 Rejections: Meeting Patent Eligibility Requirements

Leveraging Recent Decisions and USPTO Guidance to Overcome Rejections

A live 90-minute premium CLE webinar with interactive Q&A


Tuesday, February 12, 2019

1:00pm-2:30pm EST, 10:00am-11:30am PST

Early Registration Discount Deadline, Friday, January 25, 2019

or call 1-800-926-7926

This CLE webinar will guide patent counsel for overcoming Section 101 rejections for biotech patents. The panel will review recent case law and USPTO guidance on §101 patent eligibility and offer strategies to address Section 101 rejections.

Description

The number of Section 101 rejections over all types of technologies, including biotechnology and software-related patents, has dramatically increased since the Supreme Court's decision in Alice Corp. v. CLS Bank (U.S. 2014).

Review of USPTO guidance documents and art unit specific responses to Section 101 are helpful in crafting a strategy for overcoming rejections. The guidance documents attempt to summarize holdings of specific factual 101 cases and suggest a comparison of these cases to fact patterns as suitable material to support a prima facia case of ineligibility and provide guidance on eligible claims. Case law has not given sufficient information as to the test for finding the line between eligible and ineligible subject matter. It is desirable to avoid claim types that have been found ineligible by the courts. The panel will discuss these cases as well as their counterpoints, suggesting potential strategies for eligible for patent protection under Section 101.

Section 101 rejections and appeals continue to mount in numbers as examiners and PTAB judges attempt to reconcile inconsistent case law and disregard for the language of the §101 statutes. Applicants should anticipate Section 101 rejections and devise strategies to prevent or mitigate these rejections. The anticipation of an eligibility rejection and proper planning of a deliberate eligibility strategy can lead to an implementation strategy for overcoming these rejections.

Listen as our authoritative panel of patent attorneys discusses the impact of the Alice Corp. decision and the USPTO's guidance on §101 rejections. The panel will offer best practices for patent counsel on ways to overcome §101 rejections for biotech patents.

READ MORE

Outline

  1. Current guidance
    1. How the courts have applied Alice Corp. and lessons learned from those decisions
    2. USPTO guidance
  2. Strategies for overcoming §101 rejections in biotech patents
    1. Identifying and arguing deficiencies in examiner's characterization
    2. Examiner interviews
    3. Addressing the rationale behind a rejection
    4. Amending claims
    5. Improved drafting to avoid rejections

Benefits

The panel will review these and other relevant issues:

  • The impact of the Mayo, Myriad, and Ariosa decisions on recent USPTO and Federal Circuit decisions addressing §101 rejections for biotech and other technological patents
  • Problems with the USPTO guidance documents and examiner training
  • Potential strategies to overcome §101 rejection
  • Robust patent specification and claim drafting tips

Faculty

Murphy, Amanda
Amanda K. Murphy, Ph.D.

Partner
Finnegan Henderson Farabow Garrett & Dunner

Dr. Murphy focuses her practice on client counseling and patent prosecution for a range of clients. She prepares new...  |  Read More

O’Connor, Steven
Steven P. O'Connor, Ph.D.

Partner
Finnegan Henderson Farabow Garrett & Dunner

Dr. O’Connor leads the firm’s biotechnology and pharmaceutical practice group. He provides IP counseling...  |  Read More

Sukduang, Sanya
Sanya Sukduang

Partner
Finnegan Henderson Farabow Garrett & Dunner

Mr. Sukduang concentrates on patent litigation before the federal district courts and the U.S. Court of Appeals for the...  |  Read More

Live Webinar

Buy Live Webinar
Includes Early Discount Savings of $50 (through 01/25/19)

Live Webinar

$297

Buy Live Webinar & Recording
Includes special savings of $300 (through 01/25/19)

Live Webinar & Download

$394

Live Webinar & DVD

$394 + $9.45 S&H

Other Formats
— Anytime, Anywhere

Includes Early Discount Savings of $50 (through 01/25/19)

Strafford will process CLE credit for one person on each recording. All formats include program handouts. To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video

48 hours after event

$297

Download

48 hours after event

$297

DVD

10 business days after event

$297 + $9.45 S&H